Immunotoxin Therapy and Cytarabine in Treating Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Status:
Terminated
Trial end date:
2018-06-26
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and the best dose of deglycosylated ricin A
chain-conjugated anti-cluster of differentiation (CD)19/anti-CD22 immunotoxins when given
together with cytarabine in treating patients with B-cell acute lymphoblastic leukemia that
has come back after a period of improvement (relapsed) or does not respond to treatment
(refractory). Immunotoxins, such as deglycosylated ricin A chain-conjugated
anti-CD19/anti-CD22 immunotoxins, can find certain cancer cells and kill them without harming
normal cells. Drugs used in chemotherapy, such as cytarabine, work in different ways to stop
the growth of cancer cells, either by killing the cells, by stopping them from dividing, or
by stopping them from spreading. Giving deglycosylated ricin A chain-conjugated
anti-CD19/anti-CD22 immunotoxins with cytarabine may kill more cancer cells.
Phase:
Phase 1
Details
Lead Sponsor:
Albert Einstein College of Medicine Albert Einstein College of Medicine of Yeshiva University